Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Melagatran. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 20/20 | 0.63 |
| ▸ | F10 | P00742 | 1/20 | 0.56 |
| ▸ | PROC | P04070 | 1/20 | 0.56 |
| ▸ | F7 | P08709 | 1/20 | 0.56 |
| ▸ | MASP2 | O00187 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Melagatran SCHEMBL8083301 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL20567754 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL23840802 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL27652 | 0.99 | F2 (0.64) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL5706395 | 0.98 | F2 (0.63) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL27557537 | 0.98 | F2 (0.63) | F2F10PROCF7MASP2 | |
| Melagatran SCHEMBL29160734 | 0.98 | F2 (0.63) | F2F10PROCF7MASP2 | |
| SCHEMBL23793366 | 0.98 | F2 (0.62) | F2F10PROCF7MASP2 | |
| SCHEMBL23840808 | 0.95 | F2 (0.64) | F2F10PROCF7 | |
| SCHEMBL23793973 | 0.95 | F2 (0.67) | F2F10PROCF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7678782-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2010-03-16 | — | — | US | disclosed |
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2007-01-18 | — | — | US | disclosed |
| US-7144877-B2 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. (US) | 2006-12-05 | — | — | US | disclosed |
| EP-1358200-A4 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT INC (US) | 2005-07-20 | — | — | EP | disclosed |
| EP-1358200-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | Xenoport, Inc. (US) | 2003-11-05 | — | — | EP | disclosed |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | XENOPORT, INC. | 2002-07-25 | — | — | US | disclosed |
| WO-2002044324-A2 | BILE-ACID DERIVED COMPOUNDS FOR ENHANCING ORAL ABSORPTION AND SYSTEMIC BIOAVAILABILITY OF DRUGS | XENOPORT, INC. (US) | 2002-06-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070015716-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | F2 1549/4885F10 3525/4885PROC 705/4885 |
| US-20020099041-A1 | Bile-acid derived compounds for enhancing oral absorption and systemic bioavailability of drugs | SLC10A2, ABCB11, SLC10A1 | F2 1549/4885F10 3525/4885PROC 705/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.